منابع مشابه
Glucagon-Like Peptide-1 and Diabetes
This special issue was focused on the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. This gastrointestinal hormone, which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake. The response of circulating active GLP-1 concentrations after a standard meal, as well as after an oral glucose load, has been reported to be re...
متن کاملGlucagon-Like Peptide-1 and Diabetes 2012
The present special issue was aimed at elucidating the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. GLP-1 is a gastrointestinal hormone, mainly secreted after meals, capable of increasing glucose-stimulated insulin release and inhibits food intake. The physiological activity of this hormone has been demonstrated to be impaired in obese subjects and in patients wit...
متن کاملEFFECTS OF AEROBIC TRAINING ON DIPEPTIDYL PEPTIDASE-4 AND GLUCAGON-LIKE PEPTIDE-1 IN OBESE WOMEN WITH TYPE 2 DIABETES
Background: Obesity increases the risk of developing type 2 diabetes with regard to the hormones involved. The purpose of this quasi-experimental study was to investigate the effect of aerobic exercise on Dpp-4 and GLP-1 in obese women with type 2 diabetes. Methods: From among obese women with type-2 diabetes mellitus 35-50 years old referred to the Diabetes Association of Saveh, 20 people wer...
متن کاملGlucagon-Like Peptide-1
Ma Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury. It can reduce infarct size, ischemic left ventricular dysfunction, and myocardial stunning. GLP-1 receptor agonists have also been shown to reduce ...
متن کاملGlucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related condi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Experimental Diabetes Research
سال: 2011
ISSN: 1687-5214,1687-5303
DOI: 10.1155/2011/901954